BioPorto A/S launches ProNephro AKI (NGAL) for diagnostic use in the US

From GlobeNewswire: 2025-06-27 03:20:00

BioPorto A/S has announced the commercialization of ProNephro AKITM (NGAL) for diagnostic use in the US. This product is intended for risk stratification for moderate-to-severe Acute Kidney Injury in patients aged 3 months to 21 years. The first purchase order for the US market has been received, marking an important milestone for the company. ProNephro AKITM (NGAL) has FDA 510(k) marketing clearance for Roche’s cobas® c501 analyzers. This announcement does not change BioPorto’s guidance for 2025. For more information, visit BioPorto’s website or contact Jennifer Zonderman at [email protected].



Read more at GlobeNewswire: Initiation of commercialization of ProNephro AKI (NGAL) for